Grail’s cancer blood test shows ‘proof of principle,’ but challenges remain
Will Grail hit its its out-of-the-park goal of detecting tumors super-early with a blood test? The early results are in for its liquid biopsy.
A long way to go, but getting there — that’s the verdict on the highly anticipated data Grail released Saturday about its liquid biopsy for cancer.
The Illumina spinoff is almost as well known for its executive departures and ability to raise buckets of money as for its out-of-the-park goal: detecting tumors super-early, when even cancers with a horrible prognosis might be treatable, by analyzing DNA that has escaped its cells and is floating in the blood.
There are still years of work before Grail has a cancer blood test ready for clinical use. But the four studies it presented at the annual meeting of the American Society of Clinical Oncology demonstrate “a proof of
